- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen to Demonstrate Breadth of Oncology Portfolio with 41 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting
Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4469, 4680
OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection
Expanded indication includes both treatment-naïve and treatment-experienced adult patients with or without cirrhosis
Johnson & Johnson Announces Agreement To Acquire Alios BioPharma
Acquisition Strengthens Existing Pipeline in Viral Diseases
Study Observed Association between JANSSEN® CONNECT® Injection Centers and Increased Adherence to Healthcare Provider-Ordered Janssen Long-Acting Treatment for People with Schizophrenia
JANSSEN® CONNECT® program seeks to provide people living with schizophrenia information and assistance to support healthcare provider-ordered long-acting antipsychotic treatment
Johnson & Johnson Announces New Grant to Harvard Medical School to Combat Drug-Resistant Tuberculosis
New collaboration will help address significant global unmet needs in pediatric drug-resistant tuberculosis (DR-TB) treatment and optimize use of existing DR-TB treatments
New Data Show Once-Daily XARELTO® May Be an Alternative to Vitamin K Antagonists in Treating Atrial Fibrillation Patients Undergoing Elective Cardioversion
X-VeRT Study Results Presented as a Hot Line Session at the ESC Congress 2014 and Published in European Heart Journal